Global health authorities are responding to two major public health challenges as the Democratic Republic of Congo begins testing an experimental Ebola treatment while Europe grapples with a deadly heatwave that has claimed more than 1,300 lives.
In the Democratic Republic of Congo, the first patients have been enrolled in a World Health Organization-backed clinical trial aimed at finding the first effective treatment for the Bundibugyo strain of Ebola, a rare form of the virus that currently has no approved vaccine or specific therapy.
The study will evaluate the effectiveness of the antibody treatment MBP134 and the antiviral drug remdesivir, both individually and in combination, in hopes of reducing deaths from the ongoing outbreak. More than 1,400 infections and over 430 deaths have already been recorded, making the trial a significant milestone in the global response.
Health concerns have also spread beyond Africa after France confirmed its first Ebola case linked to the current outbreak. The patient, a doctor who recently returned from the DRC, is in isolation while health authorities conduct contact tracing. Officials have stressed that the risk to the wider public remains low because Ebola spreads through direct contact with the bodily fluids of an infected person.
Meanwhile, Europe continues to battle record-breaking temperatures. The World Health Organization says more than 1,300 excess deaths have been linked to the ongoing heatwave since June 21, with France accounting for around 1,000 of those deaths.
Hospitals and emergency services across several countries have reported surging demand as temperatures exceeded 40°C in parts of the continent. WHO has described heat stress as a “silent killer” and warned that Europe must adapt to increasingly frequent and intense heatwaves driven by climate change.
